| Bioactivity | HDAC6-IN-44 (compound H10) is a selective HDAC6 inhibitor with an IC50 value of 8.97 nM. HDAC6-IN-44 can inhibit the idiopathic pulmonary fibrosis (IPF) phenotype and exhibits antifibrotic activity. Additionally, HDAC6-IN-44 reduces fibrogenesis in a bleomycin-induced pulmonary fibrosis mouse model and demonstrates good metabolic stability. HDAC6-IN-44 holds promise for research in the field of idiopathic pulmonary fibrosis[1]. |
| Invitro | HDAC6-IN-44 (compound H10) (2.5-10 μM, 1-300 μM, 48 h) 以剂量依赖的方式抑制 TGF-β 诱导的 HELF 细胞增殖、细胞活力及其 HDAC6 活性，且未引起明显的细胞毒性效应[1]。HDAC6-IN-44 (2.5-10 μM, 48h) 通过作用于 HDAC6 相关信号通路干预 TGF-β1 相关的纤维化过程[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> HDAC6-IN-44 相关抗体: Cell Viability Assay[1] Cell Line: |
| In Vivo | HDAC6-IN-44 (compound H10) (0.1 mL/10g, i.p., daily for 3 weeks)对肺纤维化小鼠模型中肺组织HDAC6活性增加及胶原沉积具有显著抑制作用[1]。HDAC6-IN-44 (0.1 mL/10g, i.p., daily for 3 weeks) 能够剂量依赖性地抑制肺纤维化小鼠模型的肺纤维化的进程[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C20H21N3O3 |
| Molar Mass | 351.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Li Y, et al. Discovery of novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors for the efficient treatment of idiopathic pulmonary fibrosis (IPF) in vitro and in vivo. Eur J Med Chem. 2024 Jun 17;275:116608. |